Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation

AIDS

Volumn 24, Issue 18, 2010, Pages 2763-2771

  Busch, Michael P ^a,b   Pilcher, Christopher D ^c   Mastro, Timothy D ^d   Kaldor, John ^e   Vercauteren, Gaby ^f   Rodriguez, William ^g   Rousseau, Christine ^g   Rehle, Thomas M ^h   Welte, Alex ⁱ   Averill, Megan D ^d   Calleja, Jesus M Garcia ^e  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b Department of Laboratory Medicine ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d FAMILY HEALTH INTERNATIONAL   (United States)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

^g BILL AND MELINDA GATES FOUNDATION   (United States)

^h HUMAN SCIENCES RESEARCH COUNCIL   (South Africa)

ⁱ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

AIDS; Cross sectional incidence assays; Detuned assays; HIV; Incidence estimation

Indexed keywords

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; INCIDENCE; LABORATORY TEST; NOMENCLATURE; PRIORITY JOURNAL; REVIEW; WORLD HEALTH ORGANIZATION;

EPIDEMIOLOGIC METHODS; FORECASTING; HIV INFECTIONS; HUMANS; INCIDENCE; SENTINEL SURVEILLANCE;

EID: 78549267435     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833f1142     Document Type: Review

References (39)

1. Mastro TD, Kim A, Hallett T, Rehle T, Welte A, Laeyendecker O, et al. Estimating HIV incidence in populations using tests for recent infection: issues, challenges and the way forward. J HIV/ AIDS Surveil Epidemiol 2010 [Epub ahead of print].
2. Brown T, Salomon JA, Alkema L, Raftery AE, Gouws E. Progress and challenges in modelling country-level HIV/AIDS epidemics: the UNAIDS Estimation and Projection Package 2007. Sex Transm Infect 2008; 84 (Suppl 1):i5-i10.
3. Hallett TB, Zaba B, Todd J, Lopman B, Mwita W, Biraro S, et al. Estimating incidence from prevalence in generalised HIV epidemics: methods and validation. PLoS Med 2008; 5:e80.
4. Rehle TM, Hallett TB, Shisana O, Pillay-van Wyk V, Zuma K, Carrara H, Jooste S. A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. PLoS One 2010; 5:e11094.
5. Petersen LR, Satten GA, Dodd R, Busch M, Kleinman S, Grindon A, Lenes B. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. The HIV Seroconversion Study Group. Transfusion 1994; 34:283-289.
6. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334:1685-1690.
7. Busch MP, Lee LL, Satten GA, Henrard DR, Farzadegan H, Nelson KE, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion 1995; 35:91-97.
8. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-1879.
9. Brookmeyer R, Quinn TC. Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests. Am J Epidemiol 1995; 141:166-172.
10. Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, Swanson M, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 2002; 16:1119-1129.
11. Pilcher CD, Fiscus SA, Nguyen TQ, Foust E, Wolf L, Williams D, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med 2005; 352:1873-1883.
12. Zetola NM, Pilcher CD. Diagnosis and management of acute HIV infection. Infect Dis Clin North Am 2007; 21:19-48; vii.
13. Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, Weiblen BJ, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998; 280:42-48.
14. Rawal BD, Degula A, Lebedeva L, Janssen RS, Hecht FM, Sheppard HW, Busch MP. Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection. J Acquir Immune Defic Syndr 2003; 33:349-355.
15. Kothe D, Byers RH, Caudill SP, Satten GA, Janssen RS, Hannon WH, Mei JV. Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J Acquir Immune Defic Syndr 2003; 33:625-634.
16. McDougal JS, Pilcher CD, Parekh BS, Gershy-Damet G, Branson BM, Marsh K, Wiktor SZ. Surveillance for HIV-1 incidence using tests for recent infection in resource-constrained countries. AIDS 2005; 19 (Suppl 2):S25-30.
17. Le Vu S, Pillonel J, Semaille C, Bernillon P, Le Strat Y, Meyer L, Desenclos JC. Principles and uses of HIV incidence estimation from recent infection testing: a review. Euro Surveill 2008; 13:18969.
18. Hare CB, Pappalardo BL, Busch MP, Karlsson AC, Phelps BH, Alexander SS, et al. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis 2006; 42:700-708.
19. Parekh BS, Kennedy MS, Dobbs T, Pau CP, Byers R, Green T, et al. Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses 2002; 18:295-307.
20. Suligoi B, Galli C, Massi M, Di Sora F, Sciandra M, Pezzotti P, et al. Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassaybased method. J Clin Microbiol 2002; 40:4015-4020.
21. Suligoi B, Massi M, Galli C, Sciandra M, Di Sora F, Pezzotti P, et al. Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr 2003; 32:424-428.
22. Chawla A, Murphy G, Donnelly C, Booth CL, Johnson M, Parry JV, et al. Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. J Clin Microbiol 2007; 45:415-420.
23. Barin F, Meyer L, Lancar R, Deveau C, Gharib M, Laporte A, et al. Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J Clin Microbiol 2005; 43:4441-4447.
24. Semaille C, Barin F, Cazein F, Pillonel J, Lot F, Brand D, et al. Monitoring the dynamics of the HIV epidemic using assays for recent infection and serotyping among new HIV diagnoses: experience after 2 years in France. J Infect Dis 2007; 196:377-383.
25. Pillonel J, Barin F, Laperche S, Bernillon P, Le Vu S, Brunet S, et al. Human immunodeficiency virus type 1 incidence among blood donors in France, through 2006: use of an immunoassay to identify recent infections. Transfusion 2008; 48:1567-1575.
26. Wilson KM, Johnson EI, Croom HA, Richards KM, Doughty L, Cunningham PH, et al. Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations. AIDS 2004; 18:2253-2259.
27. Schupbach J, Gebhardt MD, Tomasik Z, Niederhauser C, Yerly S, Burgisser P, et al. Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation. PLoS Med 2007; 4:e343.
28. Barin F, Nardone A. Monitoring HIV epidemiology using assays for recent infection:where arewe? Euro Surveill 2008; 13:18967.
29. Murphy G, Parry JV. Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill 2008; 13:18966.
30. Soroka SD, Granade TC, Candal D, Parekh BS. Modification of rapid human immunodeficiency virus (HIV) antibody assay protocols for detecting recent HIV seroconversion. Clin Diagn Lab Immunol 2005; 12:918-921.
31. Kshatriya R, Cachafeiro AA, Kerr RJ, Nelson JA, Fiscus SA. Comparison of two rapid human immunodeficiency virus (HIV) assays, Determine HIV-1/2 and OraQuick Advance Rapid HIV-1/2, for detection of recent HIV seroconversion. J Clin Microbiol 2008; 46:3482-3483.
32. Wei X, Liu X, Dobbs T, Kuehl D, Nkengasong JN, Hu DJ, Parekh BS. Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retroviruses 2010; 26:61-71.
33. Laeyendecker O, Rothman RE, Henson C, Horne BJ, Ketlogetswe KS, Kraus CK, et al. The effect of viral suppression on cross-sectional incidence testing in the johns hopkins hospital emergency department. J Acquir Immune Defic Syndr 2008; 48:211-215.
34. Guy R, Gold J, Calleja JM, Kim AA, Parekh B, Busch M, et al. Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infect Dis 2009; 9:747-759.
35. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009; 83:3719-3733.
36. Hughes GJ, Fearnhill E, Dunn D, Lycett SJ, Rambaut A, Leigh Brown AJ. Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom. PLoS Pathog 2009; 5: e1000590.
37. McWalter TA, Welte A. Relating recent infection prevalence to incidence with a sub-population of assay nonprogressors. J Math Biol 2010; 60:687-710.
38. Wang R, Lagakos SW. On the use of adjusted cross-sectional estimators of HIV incidence. J Acquir Immune Defic Syndr 2009; 52:538-547.
39. McWalter TA, Welte A. A comparison of biomarker based incidence estimators. PLoS One 2009; 4:e7368.